The purpose of the present study was to correlate gyrA mutations found within in Mycobacterium tuberculosis (MTB) isolates by Genotype MTBDRsl assay with Minimum Inhibitory Concentrations (MICs) of the fluoroquinolone levofloxacin (LVX). Of the 123 archived clinical MTB isolates evaluated, 93 isolates had an Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly or His mutation and 30 were wild type. Phenotypically, gyrA mutations with Ala90Val, Ser91Pro or Asp94Ala showed a low level of resistance to LVX while Asp94Asn/Tyr, Asp94Gly or Asp94His mutations demonstrated a high level of resistance.
Inhibitory Concentrations (MICs) for 123 Mycobacterium tuberculosis (MTB) isolates that were characterized in our earlier study. 7 We correlated LVX MICs with specific gyrA mutations found via the Genotype MTBDRsl assay to determine whether these commonly occurring mutations were associated with different levels of LVX resistance.
Methods
One hundred twenty-three archived isolates were selected for which both Genotype MTBDRsl assay and drug susceptibility testing (DST) at the WHO approved critical concentrations had been performed previously. Written consent was waived for all participants as the study was carried out on archived isolates. Quantitative DST was performed via standard methods as per manufacturer instructions (Becton Dickinson Diagnostic System, Sparks, MD). 8 A stock solution of LVX was prepared by dissolving the drug in 0.1N NaOH. The drug solution was then filtered, further diluted in distilled water, and stored at −80°C for up to 6 months. A critical concentration of 1.5μg/ml was used for LVX, in accordance with WHO recommendations. 9 For estimation of LVX MICs, two concentrations below the critical concentration (0.38 and 0.75μg/ml), and three concentrations above the critical concentration (3.0, 6.0 and 12.0μg/ml), were utilized. Genotype MTBDRsl assay was performed as per manufacturer instructions (Hain Lifescience, Nehren, Germany). 10 Thirty representative isolates of the 123 MTB isolates were sequence-confirmed by PSQ. A Kruskal-Wallis statistical test (GraphPad Prism 6, oneway ANOVA) was performed.
Results
The overall agreement between Genotype MTBDRsl and phenotypic test results was 93%. Disagreement was the result of isolates with gyrA mutations that had an MIC of 1.5, as all wild-type isolates had MICs <1.5. MIC testing results for the various gyrA mutations identified via the MTBDRsl assay are summarized in Table 1 . Thirty representative isolates of the 123 MTB isolates were sequence confirmed by PSQ. These isolates were selected so as to cover all the gyrA mutations identified by the Genotype MTBDRsl assay. Four isolates with wild type characterization were also pyrosequenced. The Kruskal-Wallis test statistic was 58.44 with a p-value of <0.0001, suggesting that the levels of phenotypic resistance to LVX were significantly associated with specific gyrA mutations. The Kruskal -Wallis test results reveal that a low level of resistance to LVX was seen for isolates with Ala90Val, Ser91Pro or Asp94Ala mutations, and a high level of resistance was seen with isolates harboring Asp94Asn/Tyr, Asp94Gly or Asp94His mutations.
Discussion & Conclusion
There was a good correlation between the various gyrA mutations observed by Genotype MTBDRsl assay and the levels of phenotypic resistance seen to LVX. gyrA mutations associated with FQ resistance were found in 93 of the 123 MTB isolates evaluated. In these FQ-resistant isolates, we observed seven unique mutations: Ala90Val, Ser91Pro, Asp94Ala, Asp94Asn, Asp94Tyr, Asp94Gly and Asp94His. A significant correlation was found between the LVX MICs and the position of the gyrA mutations. A dosing of LVX at 500mg daily yields a peak serum concentration (Cmax) of 6.21μg/ml and an AUC24 value of 44.8μg*h/ml, resulting in a Cmax/MIC of 5-7 and an AUC24/MIC ratio of 40-50. 4 In the present study, 100% (25/25) of isolates with the mutation Ala90Val had an MIC at or above the critical concentration of 1.5μg/ml. Similarly, 100% (6/6) of isolates with a Ser91Pro mutation showed an MIC of 1.5-3.0μg/ml. A previous study reported similar findings, with an MIC of 1.0 μg/ml for the mutations Ala90Val, Ser91Pro and Asp94Ala. 11 MICs ranging from 3.0-12.0μg/ml for LVX were seen in 100% (42/42) of isolates with Asp94Gly mutations, in accordance with other studies reporting 60% (12/20) of the isolates with the mutation having an MIC of 10.0μg/ml. 11 Isolates with Asp94Tyr and Asp94His showed an MIC90 of 6.0μg/ml. Similar results were found in earlier study with MIC of 4μg/ml. 5 For isolates with Ala90Val, Ser91Pro or Asp94Ala mutations, MICs were below the peak serum concentration (MIC90 = 3μg/ml or 1.5μg/ml), whereas Asp94Asn/Tyr, Gly or His mutations had MICs at or above the peak serum concentration (MIC90 = 6μg/ml). Judged by MIC90, mutations at Asp94Asn/Tyr, Gly or His were linked to a higher level of resistance to LVX compared to mutations at Ala90Val, Ser91Pro or Asp94Ala. These results were similar to those MIC levels previously reported for these isolates against other FQ compounds, 7 suggesting that clinical MTB isolates with gyrA mutations in the 90 and 91 codons have the potential to be treated with standard or increased LVX dosing. Small differences discovered between the different FQ MIC findings, meanwhile, may have significant clinical implications in deciding how, and with what FQ compounds, to best treat different infections. Table 1 Levofloxacin MICs for genetically wild-type isolates and isolates determined to harbor resistance-associated mutations in the gyrA gene 
